Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

WATSON PI Form 4 May 08, 2006	HARMACEUTIC	CALS IN	C								
FORM	1									PPROVAL	
	- UNITED S	STATES		ITIES Al hington,			NGE (COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or				Estimated av burden hours		irs per					
Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed purs s Section 17(a	a) of the l		ility Hold	ling Com	ipany	Act o	ge Act of 1934, f 1935 or Sectio 40	response	0.5	
(Print or Type R	esponses)										
FEDIDA MICHAEL J Symbol WATSO			Symbol	r Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O 824 HE	(First) (N	Лiddle) Г	L	Earliest Tra ay/Year)	ansaction			_X_ Director Officer (give below)		6 Owner er (specify	
Filed(Mont			nendment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
NORWOOD), NJ 07648							Person		porting	
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactio Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3,	l (A) o l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock, par value	05/05/2006			Code V	Amount 1,667	or (D) A	Price \$ 0	(Instr. 3 and 4) 3,334 (2)	D		
\$0.0033											

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on f Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year)		e	7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Share
Non-Qualified Options to Purchase Common Stock	\$ 29.03	05/05/2006		А	5,000	05/05/2007	05/05/2016	Common Stock, par value \$0.0033	5,0

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	ŝ	Relationships						
		10% Owner	Officer	Other				
FEDIDA MICHAEL J C/O 824 HEMLOCK COURT NORWOOD, NJ 07648	X X							
Signatures								
/s/MICHAEL J. FEDIDA	05/08/2006							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The restricted stock was issued pursuant to the Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. and will vest on May 5, 2007.
- (2) This represents shares of restricted stock issued pursuant to the Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.